We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $89.9 · 21 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Corteva Nears Deal With Farmers In Pesticides Antitrust Case - Law360
Corteva Nears Deal With Farmers In Pesticides Antitrust Case Law360
DOJ backs seed patent access at Corteva-Inari hearing - Global Competition Review
DOJ backs seed patent access at Corteva-Inari hearing Global Competition Review
Corteva settles with plaintiffs in US crop protection chemical antitrust suit - MLex
Corteva settles with plaintiffs in US crop protection chemical antitrust suit MLex
US DOJ to argue at high-stakes Corteva-Inari hearing in seed patent deposit row - MLex
US DOJ to argue at high-stakes Corteva-Inari hearing in seed patent deposit row MLex
Corteva Stock: Two Businesses, One Price (NYSE:CTVA) - Seeking Alpha
Corteva Stock: Two Businesses, One Price (NYSE:CTVA) Seeking Alpha
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | After market close (AMC) | $2.23 | — | — | $6.58B | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.95 | — | — | $4.42B | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $1.35 | — | — | $12.93B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $2.1 | — | — | $10.6B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 28. | Morgan Stanley | — | Maintain | Overweight → Overweight | — | Morgan Stanley: Overweight |
| 2026. 05. 08. | UBS | — | Maintain | Neutral → Neutral | — | UBS: Neutral |
| 2026. 05. 08. | Citigroup | — | Maintain | Neutral → Neutral | — | Citigroup: Neutral |
| 2026. 04. 24. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
| 2026. 04. 22. | Oppenheimer | — | Maintain | Outperform → Outperform | — | Oppenheimer: Outperform |
| 2026. 04. 21. | Wells Fargo | — | Maintain | Overweight → Overweight | — | Wells Fargo: Overweight |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 576,940 | $38.67B | 0.06% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 67,500 | $5.65B | 0.00% | — | New position |
| 3 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 22,947 | $1.92B | 0.00% | — | New position |